Clinical Trials Logo
  1. Home
  2. Uterine Cervical Cancer
  3. NCT02036164

Adjuvant Chemotherapy for Locally Advanced Cervical Cancer — ACT-LACC  

Uterine Cervical Cancer Clinical Trial

Official title:
Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients

Clinical Trial Summary

Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We will investigate if ACT has survival benefit over CCRT alone.

Clinical Trial Description

Concurrent chemoradiation (CCRT) is the standard treatment for cervical cancer of FIGO stage IIB-IVA or so called locally advanced cervical cancer (LACC). However, failure rate after treatment is still as high as 30% to 40%.

This is a multi-center randomized controlled trial which evaluates whether adjuvant chemotherapy (ACT) after CCRT will improve treatment outcome comparing to CCRT alone. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02036164
Study type Interventional
Source Navamindradhiraj University
Contact Siriwan Tangjitgamol, MD
Phone 66-86-3841431
Email siriwanonco@yahoo.com
Status Recruiting
Phase Phase 3
Start date January 2014
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Completed NCT05022511 - Three Birds With One Stone N/A
Recruiting NCT04857528 - Detecting HPV DNA in Anal and Cervical Cancers
Completed NCT01755897 - A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients N/A
Recruiting NCT01667211 - Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer Phase 2
Active, not recruiting NCT01226264 - Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence N/A
Recruiting NCT03961191 - DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
Not yet recruiting NCT06254846 - Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study). N/A
Enrolling by invitation NCT01393470 - Evaluation of Long-term HPV Vaccine Efficacy N/A
Terminated NCT00421096 - Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer Phase 2
Terminated NCT01284348 - To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT03961178 - A Cohort Study for the Following up of Conization
Terminated NCT02317302 - FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer Phase 1
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Completed NCT00184093 - Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma Phase 1/Phase 2
Recruiting NCT03960879 - DNA Methylation for Screening Uterine Cervical Lesions
Recruiting NCT04886700 - Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer Phase 2
Completed NCT02095119 - A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer Phase 1/Phase 2
Enrolling by invitation NCT05231993 - Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening N/A
Recruiting NCT04974424 - Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV